HRP20100700T1 - Vr1 benzimidazol modulatori - Google Patents

Vr1 benzimidazol modulatori Download PDF

Info

Publication number
HRP20100700T1
HRP20100700T1 HR20100700T HRP20100700T HRP20100700T1 HR P20100700 T1 HRP20100700 T1 HR P20100700T1 HR 20100700 T HR20100700 T HR 20100700T HR P20100700 T HRP20100700 T HR P20100700T HR P20100700 T1 HRP20100700 T1 HR P20100700T1
Authority
HR
Croatia
Prior art keywords
phenyl
benzimidazol
vinyl
trifluoromethyl
benzenesulfonamide
Prior art date
Application number
HR20100700T
Other languages
English (en)
Croatian (hr)
Inventor
L. Calvo Raul
R. Player Mark
L. Dax Scott
H. Parsons William
Brandt Michael
Patel Sharmila
Liu Jian
S. Cheung Wing
C. Jetter Michele
Lee Yu-Kai
A. Youngman Mark
Pan Wenxi
M. Wells Keneth
A. Beauchamp Derek
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of HRP20100700T1 publication Critical patent/HRP20100700T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HR20100700T 2006-05-03 2010-12-17 Vr1 benzimidazol modulatori HRP20100700T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79750406P 2006-05-03 2006-05-03
PCT/US2007/066748 WO2007130780A2 (fr) 2006-05-03 2007-04-17 Modulateurs des récepteurs vr1 dérivés du benzimidazole

Publications (1)

Publication Number Publication Date
HRP20100700T1 true HRP20100700T1 (hr) 2011-02-28

Family

ID=38566108

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100700T HRP20100700T1 (hr) 2006-05-03 2010-12-17 Vr1 benzimidazol modulatori

Country Status (37)

Country Link
US (3) US7951829B2 (fr)
EP (1) EP2021330B1 (fr)
JP (1) JP5302884B2 (fr)
KR (1) KR101434883B1 (fr)
CN (1) CN101511797B (fr)
AR (1) AR060840A1 (fr)
AT (1) ATE482201T1 (fr)
AU (1) AU2007248341C1 (fr)
BR (1) BRPI0709803B8 (fr)
CA (1) CA2651128C (fr)
CO (1) CO6160329A2 (fr)
CR (1) CR10479A (fr)
CY (1) CY1111269T1 (fr)
DE (1) DE602007009378D1 (fr)
DK (1) DK2021330T3 (fr)
EA (1) EA019386B1 (fr)
EC (1) ECSP088854A (fr)
ES (1) ES2350959T3 (fr)
HK (1) HK1131971A1 (fr)
HR (1) HRP20100700T1 (fr)
IL (1) IL194916A (fr)
JO (1) JO3602B1 (fr)
MX (1) MX2008014108A (fr)
MY (1) MY154595A (fr)
NI (1) NI200800290A (fr)
NO (1) NO341965B1 (fr)
NZ (1) NZ572251A (fr)
PE (1) PE20080065A1 (fr)
PL (1) PL2021330T3 (fr)
PT (1) PT2021330E (fr)
RS (1) RS51473B (fr)
SI (1) SI2021330T1 (fr)
TW (1) TWI419882B (fr)
UA (1) UA94749C2 (fr)
UY (1) UY30322A1 (fr)
WO (1) WO2007130780A2 (fr)
ZA (1) ZA200810234B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5746471B2 (ja) 2006-12-15 2015-07-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ ベンゾイミダゾール系ｔｒｐｖ１阻害剤
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
WO2009079000A1 (fr) * 2007-12-17 2009-06-25 Janssen Pharmaceutica N.V. Modulateurs imidazolopyrimidines de trpv1
EP2224929B1 (fr) * 2007-12-17 2016-05-04 Janssen Pharmaceutica, N.V. Modulateurs imidazolo-, oxazolo- et thiazolopyrimidines de trpv1
EP2264031B1 (fr) * 2008-04-18 2015-04-15 Daewoong Pharmaceutical Co., Ltd. Nouveau dérivé de benzoxazine benzimidazole, composition pharmaceutique le comprenant et application s'y rapportant
US8232409B2 (en) 2008-10-15 2012-07-31 Janssen Pharmaceutica N.V. Heterocyclic benzimidazoles as TRPM8 modulators
US8217060B2 (en) * 2009-05-15 2012-07-10 Janssen Pharmaceutica, Nv Benzimidazole derivatives useful as TRP M8 receptor modulators
US8323805B2 (en) * 2009-06-04 2012-12-04 Nitto Denko Corporation Emissive aryl-heteroaryl acetylenes
CN102002010A (zh) * 2009-08-31 2011-04-06 住友化学株式会社 双噁唑啉基烷烃化合物的精制方法
TWI520951B (zh) 2011-05-16 2016-02-11 塞爾西優蒂克斯公司 用於治療粘膜炎的化合物
US9056874B2 (en) 2012-05-04 2015-06-16 Novartis Ag Complement pathway modulators and uses thereof
JP6387391B2 (ja) 2013-03-14 2018-09-05 ノバルティス アーゲー 眼科疾患の処置に有用な補体因子Ｂ阻害剤としての２−（１Ｈ−インドール−４−イルメチル）−３Ｈ−イミダゾ［４，５−ｂ］ピリジン−６−カルボニトリル誘導体
JP6478991B2 (ja) * 2013-07-11 2019-03-06 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｄｏ阻害剤
US9676728B2 (en) 2013-10-30 2017-06-13 Novartis Ag 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
CN108026071A (zh) * 2015-09-08 2018-05-11 住友化学株式会社 制备三唑化合物的方法
WO2018085171A1 (fr) 2016-11-01 2018-05-11 Merck Sharp & Dohme Corp. Modulateurs allostériques hétéroaryle bicycliques substitués de récepteurs nicotiniques de l'acétylcholine
CA3097519A1 (fr) * 2018-05-03 2019-11-07 Jiangsu Hengrui Medicine Co., Ltd. Derives de benzimidazole en tant que modulateurs du recepteur gamma orphelin associe aux retinoides (rorg) et leurs utilisations pharmaceutiques
CN108997398B (zh) * 2018-07-23 2020-12-15 被忽略疾病药物研发组织 一种3,3-二甲基苯并[c][1,2]氧杂戊硼烷-1(3h)-醇的制备方法
TW202118751A (zh) * 2019-10-31 2021-05-16 大陸商江蘇恒瑞醫藥股份有限公司 RORγ調節劑的酸加成鹽
CN112745268B (zh) * 2019-10-31 2022-09-16 江苏恒瑞医药股份有限公司 苯并咪唑衍生物的晶型及制备方法
US11771694B2 (en) 2020-06-05 2023-10-03 Innovation Pharmaceuticals Inc. Arylamide compounds for treatment and prevention of viral infections

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612360A (en) * 1992-06-03 1997-03-18 Eli Lilly And Company Angiotensin II antagonists
US6299796B1 (en) 1997-12-18 2001-10-09 Fuji Photo Film Co., Ltd. Styryl compound, method for the preparation thereof and electroluminescent element employing the same
US6748803B1 (en) * 2000-02-22 2004-06-15 Simmonds Precison Products, Inc. Liquid measurement system and shared interface apparatus for use therein
AU2003301436A1 (en) * 2002-10-17 2004-05-04 Amgen Inc. Benzimidazole derivatives and their use as vanilloid receptor ligands
TW200418806A (en) * 2003-01-13 2004-10-01 Fujisawa Pharmaceutical Co HDAC inhibitor
RU2373204C2 (ru) * 2003-07-28 2009-11-20 Янссен Фармацевтика Н.В. Бензимидазольные, бензтиазольные и бензоксазольные производные и их применение в качестве модуляторов lta4h
RU2006118312A (ru) * 2003-10-28 2007-12-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) Бензимидазолы, полезные в качестве модуляторов ионных каналов
WO2006058338A2 (fr) * 2004-11-29 2006-06-01 Janssen Pharmaceutica N.V. Modulateurs de 4-piperidinecarboxamide du recepteur vanilloide vr1
CA2654246A1 (fr) * 2006-07-04 2008-01-10 Janssen Pharmaceutica N.V. Agonistes cannabinoides de type benzimidazole portant un groupement heterocyclique substitue
JP5746471B2 (ja) * 2006-12-15 2015-07-08 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ ベンゾイミダゾール系ｔｒｐｖ１阻害剤

Also Published As

Publication number Publication date
MX2008014108A (es) 2008-11-14
NO341965B1 (no) 2018-03-05
KR101434883B1 (ko) 2014-08-27
ECSP088854A (es) 2008-11-27
CO6160329A2 (es) 2010-05-20
PE20080065A1 (es) 2008-02-25
TWI419882B (zh) 2013-12-21
CR10479A (es) 2009-03-31
CA2651128A1 (fr) 2007-11-15
NI200800290A (es) 2012-01-30
ES2350959T3 (es) 2011-01-28
EA019386B1 (ru) 2014-03-31
NO20085031L (no) 2009-01-06
AR060840A1 (es) 2008-07-16
ATE482201T1 (de) 2010-10-15
PT2021330E (pt) 2010-12-03
CA2651128C (fr) 2014-09-02
ZA200810234B (en) 2010-02-24
HK1131971A1 (en) 2010-02-12
UA94749C2 (en) 2011-06-10
DE602007009378D1 (de) 2010-11-04
BRPI0709803B8 (pt) 2021-05-25
AU2007248341C1 (en) 2013-01-17
JP2009535414A (ja) 2009-10-01
NZ572251A (en) 2010-08-27
US20110190344A1 (en) 2011-08-04
EA200870497A1 (ru) 2009-06-30
KR20090008428A (ko) 2009-01-21
DK2021330T3 (da) 2010-12-06
EP2021330B1 (fr) 2010-09-22
BRPI0709803B1 (pt) 2019-12-10
JP5302884B2 (ja) 2013-10-02
RS51473B (en) 2011-04-30
CY1111269T1 (el) 2015-08-05
IL194916A (en) 2013-01-31
TW200808738A (en) 2008-02-16
MY154595A (en) 2015-06-30
US7951829B2 (en) 2011-05-31
AU2007248341B2 (en) 2011-12-08
BRPI0709803A2 (pt) 2011-07-26
WO2007130780A2 (fr) 2007-11-15
UY30322A1 (es) 2007-08-31
SI2021330T1 (sl) 2011-01-31
CN101511797A (zh) 2009-08-19
IL194916A0 (en) 2009-08-03
JO3602B1 (ar) 2020-07-05
US20070259936A1 (en) 2007-11-08
US20110190364A1 (en) 2011-08-04
EP2021330A2 (fr) 2009-02-11
PL2021330T3 (pl) 2011-03-31
CN101511797B (zh) 2013-01-02
WO2007130780A3 (fr) 2008-02-14
AU2007248341A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
HRP20100700T1 (hr) Vr1 benzimidazol modulatori
EP1773330B1 (fr) Pyrazoles substitues, compositions contenant de tels composes et leurs methodes d'utilisation
JP2008502700A5 (fr)
ZA200304482B (en) Pyrimidineamines as angiogenesis modulators
US9132136B2 (en) Pharmaceutical combination
Ognyanov et al. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure− activity relationships of 2-piperazin-1-yl-1 H-benzimidazoles
HRP20100611T1 (hr) Novi spojevi
HRP20220314T1 (hr) Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao plazma kallikrein inhibitori
Bucolo et al. Controversies in glaucoma: current medical treatment and drug development
FI3743406T3 (fi) Tmem16a-modulaattoreita
JP2011042668A5 (fr)
RU2007101073A (ru) Пятичленные гетероциклы, применимые в качестве ингибиторов сериновой протеазы
JP2010513304A5 (fr)
TW200811112A (en) Benzimidazole derivatives
RU2010110640A (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2007533732A (ja) 線維症を処置するためのｃ−ｋｉｔ阻害剤の使用法
NZ525330A (en) Substituted 2-phenylaminoimidazoline phenyl ketone derivatives as IP antagonists
KR20120092655A (ko) Ｃｎｓ 장애 치료용 옥사졸린 유도체
US20060004075A1 (en) Substituted aryl amides as IP antagonists
US6548502B2 (en) Dopamine D4 ligands for the treatment of novelty-seeking disorders
Quaglia et al. α2C-adrenoceptor modulators: a patent review
CN110337292A (zh) 医药品
KR101477872B1 (ko) 신규한 벤즈이미다졸 유도체 및 ｆｘｒ 작용제로서의 그의 용도
JP2004530650A5 (fr)
HRP20230793T1 (hr) Derivati indola i benzimidazola kao dvojni antagonisti 5-ht2a i 5-ht6 receptora